Are Peptides Legal in the US? Prescription Rules and the Grey Market

Three things have to be true at once, and a legitimate provider can evidence all three.

Telemedicine satisfies the first requirement where state rules allow it, which is why peptide telehealth exists at all. States differ on what kind of encounter establishes the relationship, and a provider operating properly is licensed where you live rather than where it is headquartered.

None of the peptides discussed here are controlled substances under the Controlled Substances Act. That is why possession is not a scheduling question, and it is also why the meaningful controls are the prescription requirement and the pharmacy rules rather than criminal law.

"For an identified individual patient" is the load-bearing phrase

Section 503A requires that the drug be "compounded for an identified individual patient based on the receipt of a valid prescription order." That phrase separates lawful compounding from unlawful manufacturing. A pharmacy filling named prescriptions is compounding; an operation producing the same preparation in volume for whoever buys it is manufacturing without an approved application, and does not get the exemption. The test you can apply yourself is whether your name is on the vial, alongside the medication, the strength and the directions. A product arriving in generic packaging with no patient name was not compounded for you.

Why none of this is a scheduling question

The DEA publishes its schedules as an alphabetical list of controlled substances. None of the peptides discussed here appear on it — not BPC-157, not semaglutide or tirzepatide, not tesamorelin, not the growth-hormone-axis peptides.

That cuts two ways. There is no DEA registration question and no criminal possession statute in play. It also means the prescription requirement and the pharmacy rules are the only real controls on these medications — so a provider who treats them casually is not lightly regulated, it is operating outside the only regulation there is.

The practical consequence for you:

• A peptide that was on a provider's menu last year may not be on it this year.
• A pharmacy that stops filling something is following the rule, not failing you.
• A provider that keeps selling a substance after its pharmacy will no longer compound it is not sourcing from that pharmacy.
• "Available elsewhere" is usually a grey-market seller, not a better-informed pharmacy.

The mechanics of who may compound what are in what is a 503A compounding pharmacy.

What a menu change looks like from the inside

From the outside it can look arbitrary; the sequence is not. FDA updates its nominated-substances document, the pharmacy's regulatory team reads it and decides what it will compound from that date, the prescriber is notified, open prescriptions are reviewed, and affected patients are moved to an alternative. Nothing about the molecule changed overnight — what changed is whether the pharmacy can stand behind compounding it. A provider that quietly keeps taking orders through that sequence has either changed pharmacy without telling you, or was never using the one it named.

FDA's personal importation page states the default plainly: "in most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use because these products purchased from other countries often have not been approved by the FDA." Peptides ordered from overseas sit squarely in that description, and a shipment stopped at the border is not a negotiation you win.

FDA does describe situations where its personnel may exercise discretion — broadly, a product for a serious condition with no effective domestic treatment, not commercialised in the US, presenting no unreasonable risk, with a written affirmation that it is for personal use, limited to "generally not more than a three month supply," and supported by documentation from a US licensed physician or evidence of continuing a treatment begun abroad.

That is a narrow door, and wellness peptides ordered from an overseas website do not walk through it. The useful takeaway is not that importing is criminal for you — it is that the route has no floor: no recourse if the shipment vanishes, no accountability for what is in the vial, and no prescriber.

You will occasionally see peptides sold as capsules or sprays labelled as dietary supplements. The statutory definition makes that a difficult position to hold. A dietary supplement under 21 U.S.C. § 321(ff) must be a vitamin, mineral, herb, amino acid or related constituent intended for ingestion and labeled as such — and the definition expressly excludes an article "approved as a new drug under section 355" or "authorized for investigation as a new drug" for which substantial clinical investigations have been instituted and made public. Several peptides have been the subject of exactly such investigations. And the definition of "drug" reaches any article other than food "intended to affect the structure or any function of the body." A product marketed for what peptides are marketed for is describing a drug, whatever the label says.

What the states control

The federal rules above are uniform. The state layer is not, and it decides your actual experience. States set what kind of encounter creates a physician–patient relationship, whether an asynchronous telemedicine intake suffices, whether a video or telephone consultation is required, and what must be documented. States license the pharmacy and register out-of-state pharmacies that ship in. Some impose additional requirements on compounded sterile preparations or on specific categories of medication.

Why we do not publish a state-by-state legal chart

Because it would be wrong within a quarter, and because a chart is the wrong instrument. State rules change on their own timetable, boards issue guidance between rule changes, and the interaction between a medical board position and a pharmacy board position is not something a table captures. What you can do instead takes a minute: confirm the prescriber is licensed in your state, ask which pharmacy will dispense and where it is licensed, and verify both with the relevant boards. That answers your state question definitively, today, which no chart can.

What approval actually certifies

Two things are commonly confused and should not be. Not FDA approved does not mean illegal: approval applies to a manufactured product that went through the approval process, while lawful compounding is a different pathway with its own oversight. And FDA registration of a pharmacy is not FDA approval of a drug. A provider using those interchangeably is either careless or hoping you will not notice. Compounded medications are not FDA approved — FDA states it directly: "compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."

What oversight a 503A pharmacy is actually under

The oversight is real but it is not product approval. FDA describes the split: "state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies," while FDA conducts surveillance and for-cause inspections. Drugs compounded under 503A are not subject to current good manufacturing practice requirements; drugs compounded in a 503B outsourcing facility are, and those facilities are inspected by FDA on a risk-based schedule.

So the accurate framing of a compounded BPC-157 vial is: prepared by a pharmacist licensed by a state board, in a pharmacy that board inspects, on a prescription written for you by a physician licensed in your state, from a bulk substance the pharmacy has satisfied itself qualifies under 503A. That is a genuine chain of accountability. It is not FDA approval, and anyone telling you it is has stopped being useful to you.

The legal framework above is settled and documentable: section 503A of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013, state pharmacy licensure, and state medical practice acts. What is genuinely unsettled is the regulatory status of individual peptide substances, which is under active review and moves. Separately, legality says nothing about evidence. For most of the wellness peptides the published research is preclinical: animal and cell work rather than large randomised human trials. Lawful, prescribed and well made is not the same as proven, and an honest prescriber will say so.

Where the human evidence is genuinely strong

The generalisation has real exceptions and it is dishonest to flatten them. Semaglutide and tirzepatide have among the largest randomised trial programmes in modern medicine — the STEP and SELECT trials for semaglutide, the SURMOUNT and SURPASS programmes for tirzepatide, in the New England Journal of Medicine and The Lancet. Tesamorelin was studied in randomised placebo-controlled phase 3 trials in people with HIV-associated abdominal fat accumulation, reported in the New England Journal of Medicine in 2007 and later in JAMA and Lancet HIV. Bremelanotide, the molecule dispensed as PT-141, was studied in randomised trials in premenopausal women with hypoactive sexual desire disorder, reported in Obstetrics & Gynecology in 2019 and in the Journal of Women's Health in 2022.

Where it is not

BPC-157, by contrast, has no large randomised controlled trials in humans. The literature is animal and cell research, and the honest framing is "described in preclinical research and used clinically," not "proven in people." Both statements can be true about the same catalogue, and a reference that will not distinguish between them is not worth reading. Are peptides safe long term covers what is and is not known.